[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636190":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":23,"collaborators":11,"id":27,"slug":11,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":30,"acronym":11,"eligibilityCriteria":31,"healthyVolunteers":28,"sex":32,"minAge":33,"maxAge":11,"enrollmentInfo":34,"targetDuration":11,"studyType":37,"phases":38,"briefSummary":40,"conditions":41,"keywords":11,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":11},{"fullName":5,"class":6},"Capital Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"RIC group","EXPERIMENTAL",null,[13],"Device: RIC",{"label":15,"type":16,"description":11,"interventionNames":11},"Control group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DEVICE","RIC","Participants will undergo a 7-day remote ischemic conditioning (RIC) intervention prior to ascending to high altitude. On the day following the completion of the RIC intervention, they will ascend to a high-altitude region (\\>2500 m). Standardized RIC treatment will be administered using a dedicated RIC device. Each intervention session consists of 5 cycles. Every cycle includes 5 minutes of bilateral upper limb ischemia followed by 5 minutes of reperfusion. The cuff pressure for inducing ischemia is set at 200 mmHg. The intervention is administered twice daily for 90 consecutive days.",[9],{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ji Xunming,MD,PhD","PhD","100636190",false,"NCT07562464","Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations","Inclusion Criteria:\n\nAged ≥18 years, of either sex; Continuous residence in a high-altitude region (≥2500 meters) for more than 6 months, with no plan for long-term departure from the plateau during the study period; Meeting the diagnostic criteria for high-altitude polycythemia; Willing to provide written informed consent.\n\nExclusion Criteria:\n\nOther hematologic diseases, such as anemia or abnormal leukocytosis; Severe dysfunction of vital organs (e.g., heart, liver, kidney, lungs); Active malignancy, uncontrolled hyperthyroidism, active autoimmune disease, or poorly controlled diabetes mellitus; Pregnancy, planned pregnancy, or lactation for female participants; Contraindications to RIC (e.g., severe peripheral arterial disease, venous thrombosis, or soft tissue injury in the upper limbs); Any other condition deemed by the investigator to be unsuitable for participation in the study.","ALL","18 Years",{"count":35,"type":36},222,"ESTIMATED","INTERVENTIONAL",[39],"PHASE3","This study is a multicenter, prospective, randomized, open-label, parallel-controlled clinical trial. The participants are adult patients with high-altitude polycythemia who have been long-term residents (for \\>6 months) in regions at an altitude of ≥2500 meters. Participants are randomly assigned to one of two groups: a conventional medication group and a remote ischemic conditioning (RIC) intervention group. The study aims to evaluate the effectiveness of a standardized 90-day RIC intervention, as an add-on to conventional medication, in managing high-altitude polycythemia.",[42],"High Altitude Polycythemia","NOT_YET_RECRUITING","2026-04-25",{"date":46,"type":47},"2026-05-01","ACTUAL",{"date":49,"type":36},"2026-05-20",{"date":51,"type":36},"2028-06-30",{"name":5,"class":6}]